Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition

British Journal of Pharmacology

Volumn 169, Issue 8, 2013, Pages 1849-1861

  Ferrandi, Mara ^a   Barassi, Paolo ^a   Tadini Buoninsegni, Francesco ^b   Bartolommei, Gianluca ^b   Molinari, Isabella ^a   Tripodi, Maria Grazia ^a   Reina, Cristina ^a   Moncelli, Maria Rosa ^b   Bianchi, Giuseppe ^c,d   Ferrari, Patrizia ^a  

^a Prassis Sigma Tau Research Institute   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d CVie Therapeutics   (Hong Kong)

Author keywords

calcium uptake; charge measurements; heart failure; inotropy; istaroxime; lusitropy; phospholamban; sarcoplasmic reticulum Ca2+ ATPase; SERCA

Indexed keywords

CALCIUM ION; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIGOXIN; ISTAROXIME; PHOSPHOLAMBAN; PROTEIN SERCA2A; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM TRANSPORT; CELL VACUOLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME CONFORMATION; HEART FAILURE; INSECT CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOPLASMIC RETICULUM; SPODOPTERA FRUGIPERDA;

CALCIUM UPTAKE; CHARGE MEASUREMENTS; HEART FAILURE; INOTROPY; ISTAROXIME; LUSITROPY; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CA2+ ATPASE; SERCA;

ANIMALS; CALCIUM; CALCIUM-BINDING PROTEINS; DOGS; ETIOCHOLANOLONE; GUINEA PIGS; HEART FAILURE; HUMANS; MALE; MICROSOMES; RABBITS; SARCOPLASMIC RETICULUM; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SPODOPTERA;

EID: 84881322149     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12278     Document Type: Article

References (45)

1. Adamson PB, Vanoli E, Mattera GG, Germany R, Gagnol JP, Carminati P, et al. (2003). Hemodynamic effects of a new inotropic compound, PST2744, in dogs with chronic ischemic heart failure. J Cardiovasc Pharmacol 42: 169-173.
2. Alemanni M, Rocchetti M, Re D, Zaza A, (2011). Role and mechanism of subcellular Ca2+ distribution in the action of two inotropic agents with different toxicity. J Mol Cell Cardiol 50: 910-918.
3. Asahi M, Kimura Y, Kurzydlowski K, Tada M, MacLennan DH, (1999). Transmembrane helix M6 in sarco(endo)plasmic reticulum Ca(2+)-ATPase forms a functional interaction site with phospholamban. Evidence for physical interactions at other sites. J Biol Chem 274: 32855-32862.
4. Bartolommei G, Tadini-Buoninsegni F, Moncelli MR, Gemma S, Camodeca C, Butini S, et al. (2011). The Ca2+-ATPase (SERCA1) is inhibited by 4-aminoquinoline derivatives through interference with catalytic activation by Ca2+, whereas the ATPase E2 state remains functional. J Biol Chem 286: 38383-38389.
5. Bers DM, (2002). Cardiac excitation-contraction coupling. Nature 415: 198-205.
6. Bers DM, (2006). Altered cardiac myocyte Ca regulation in heart failure. Physiology 21: 380-387.
7. Bidwell P, Blackwell DJ, Hou Z, Zima AV, Robia SL, (2011). Phospholamban binds with differential affinity to calcium pump conformers. J Biol Chem 286: 35044-35050.
8. Chen Z, Akin BL, Stokes DL, Jones LR, (2006). Cross-linking of C-terminal residues of phospholamban to the Ca2+ pump of cardiac sarcoplasmic reticulum to probe spatial and functional interactions within the transmembrane domain. J Biol Chem 281: 14163-14172.
9. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, et al. (2002). Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287: 1541-1547.
10. Del Monte F, Harding SE, Schmidt U, Matsui T, Kang ZB, Dec GW, et al. (1999). Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation 100: 2308-2311.
11. Gheorghiade M, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, et al. (2008). Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 51: 2276-2285.
12. Gustavsson M, Traaseth NJ, Karim CB, Lockamy EL, Thomas DD, Veglia G, (2011). Lipid-mediated folding/unfolding of phospholamban as a regulatory mechanism for the sarcoplasmic reticulum Ca2+-ATPase. J Mol Biol 408: 755-765.
13. Hasenfuss G, (1998). Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 37: 279-289.
14. James ZM, McCaffrey JE, Torgersen KD, Karim CB, Thomas DD, (2012). Protein-protein interactions in calcium transport regulation probed by saturation transfer electron paramagnetic resonance. Biophys J 103: 1370-1378.
15. Karim CB, Zhang Z, Howard EC, Torgersen KD, Thomas DD, (2006). Phosphorylation-dependent conformational switch in spin-labeled phospholamban bound to SERCA. J Mol Biol 358: 1032-1040.
16. Katz A, Lifshitz Y, Bab-Dinitz E, Kapri-Pardes E, Goldshleger R, Tal DM, et al. (2010). Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase. J Biol Chem 285: 19582-19592.
17. Kawase Y, Ly HQ, Prunier F, Lebeche D, Shi Y, Jin H, et al. (2008). Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol 51: 1112-1119.
18. + (ATP7A/B) ATPases. J Biol Chem 287: 32717-32727.
19. Mahaney JE, Autry JM, Jones LR, (2000). Kinetics studies of the cardiac Ca-ATPase expressed in Sf21 cells: new insights on Ca-ATPase regulation by phospholamban. Biophys J 78: 1306-1323.
20. Mann DL, Bristow MR, (2005). Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111: 2837-2849.
21. Mattera GG, Lo Giudice P, Loi FM, Vanoli E, Gagnol JP, Borsini F, et al. (2007). Istaroxime: a new luso-inotropic agent for heart failure. Am J Cardiol 99 (2A): 33A-40A.
22. Micheletti R, Mattera GG, Rocchetti M, Schiavone A, Loi MF, Zaza A, et al. (2002). Pharmacological profile of the novel inotropic agent (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744). J Pharmacol Exp Ther 303: 592-600.
23. Micheletti R, Palazzo F, Barassi P, Giacalone G, Ferrandi M, Schiavone A, et al. (2007). Istaroxime, a stimulator of Sarcoplasmic Reticulum Calcium Adenosine Triphosphatase Isoform 2a activity, as a novel therapeutic approach to heart failure. Am J Card 99: 24A-32A.
24. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, et al. (1999). Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99: 313-322.
25. Nediani C, Fiorillo C, Marchetti E, Pacini A, Liguri G, Nassi P, (1996). Stimulation of cardiac sarcoplasmic reticulum calcium pump by acylphosphatase. J Biol Chem 271: 19066-19073.
26. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. (1991). Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325: 1468-1475.
27. Pintschovius J, Fendler K, (1999). Charge translocation by the Na+/K+-ATPase investigated on solid supported membranes: rapid solution exchange with a new technique. Biophys J 76: 814-826.
28. Rocchetti M, Besana A, Mostacciuolo G, Ferrari P, Micheletti R, Zaza A, (2003). Diverse toxicity associated with cardiac Na+/K+ pump inhibition: evaluation of electrophysiological mechanisms. J Pharmacol Exp Ther 305: 765-771.
29. Rocchetti M, Besana A, Mostacciuolo G, Micheletti R, Ferrari P, Sarkozi S, et al. (2005). Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2- aminoethoxy)imino)androstane-6,17-dione hydrochloride]. J Pharmacol Exp Ther 313: 207-215.
30. Rocchetti M, Alemanni M, Mostacciuolo G, Barassi P, Altomare C, Chisci R, et al. (2008). Modulation of sarcoplasmic reticulum function by PST2744 [istaroxime; (E,Z)-3-((2-aminoethoxy)imino) androstane-6,17-dione hydrochloride)] in a pressure-overload heart failure model. J Pharmacol Exp Ther 326: 957-965.
31. Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, et al. (1991). A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 260: H1379-H1384.
32. Sabbah HN, Imai M, Cowart D, Amato A, Carminati P, Gheorghiade M, (2007). Hemodynamic properties of a new-generation positive luso-inotropic agent for the acute treatment of advanced heart failure. Am J Cardiol 99 (2A): 41A-46A.
33. Sagara Y, Inesi G, (1991). Inhibition of the sarcoplasmic reticulum Ca2+ transport ATPase by thapsigargin at subnanomolar concentrations. J Biol Chem 266: 13503-13506.
34. 2+-ATPase of sarcoplasmic reticulum. J Biol Chem 264: 17816-17823.
35. Shah SJ, Blair JE, Filippatos GS, Macarie C, Ruzyllo W, Korewicki J, et al. (2009). Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-HF) trial. Am Heart J 157: 1035-1041.
36. Tadini-Buoninsegni F, Bartolommei G, Moncelli MR, Inesi G, Guidelli R, (2004). Time-resolved charge translocation by sarcoplasmic reticulum Ca-ATPase measured on a solid supported membrane. Biophys J 86: 3671-3686.
37. Tadini-Buoninsegni F, Bartolommei G, Moncelli MR, Guidelli R, Inesi G, (2006). Pre-steady state electrogenic events of Ca2+/H+ exchange and transport by the Ca2+-ATPase. J Biol Chem 281: 37720-37727.
38. 2+ ATPase). Mol Pharmacol 73: 1134-1140.
39. Tadini-Buoninsegni F, Bartolommei G, Moncelli MR, Fendler K, (2008b). Charge transfer in P-type ATPases investigated on planar membranes. Arch Biochem Biophys 476: 75-86.
40. +-ATPase is demonstrated by pre-steady state electrical measurements. FEBS Lett 584: 4619-4622.
41. Tocchetti CG, Wang W, Froehlich JP, Huke S, Aon MA, Wilson GM, et al. (2007). Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca2+ cycling. Circ Res 100: 96-104.
42. Toyoshima C, Asahi M, Sugita Y, Khanna R, Tsuda T, MacLennan DH, (2003). Modeling of the inhibitory interaction of phospholamban with the Ca2+ ATPase. Proc Natl Acad Sci U S A 100: 467-472.
43. Traaseth NJ, Thomas DD, Veglia G, (2006). Effects of Ser16 phosphorylation on the allosteric transitions of phospholamban/Ca(2+)-ATPase complex. J Mol Biol 358: 1041-1050.
44. Winther AM, Bublitz M, Karlsen JL, Møller JV, Hansen JB, Nissen P, et al. (2013). The sarcolipin-bound calcium pump stabilizes calcium sites exposed to the cytoplasm. Nature 495: 265-269.
45. Zamoon J, Nitu F, Karim C, Thomas DD, Veglia G, (2005). Mapping the interaction surface of a membrane protein: unveiling the conformational switch of phospholamban in calcium pump regulation. Proc Natl Acad Sci U S A 102: 4747-4752.